Alcon Research
CompanySwitzerland
Alcon Research develops 5 assets, the furthest in phase 3 (Vigadexa in cataract). Mostly device and small molecule acting on NR3C1 and inflammation; based in Switzerland.
- 5
- Assets
- Furthest stage
- Phase 3
- 7
- Trials
- 5
- Signals
Pipeline
5Topical combination of moxifloxacin (antibacterial) and dexamethasone (corticosteroid anti-inflammatory).
Phase 3, Small molecule, NR3C1, Inflammation, cataract, ocular inflammation associated with blepharaconjunctivitis
Replaces the natural lens to provide vision at far, intermediate, and near distances.
Human trials, Device, aphakia, presbyopia
Replaces the natural lens to provide vision at far, intermediate, and near distances while correcting astigmatism.
Human trials, Device, aphakia, presbyopia
2 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms3
- Trials9
- Signals6
- Integrity notices1
- Similar companies6